Regular therapy with the radiolabeled somatostatin analog 177Lu-octreotate (22.2–29.6
GBq) in patients with gastroenteropancreatic or bronchial neuroendocrine tumors results in …

Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-
growing tumors, which frequently express somatostatin receptors on their cell membranes …

Purpose Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients
with a somatostatin receptor-positive neuroendocrine tumour (NET). Still unclear is how …

Purpose Treatment with the radiolabelled somatostatin analogue 177 Lu-octreotate results
in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine …

Background Peptide receptor radiation therapy (PRRT) using [177 Lu-DOTA 0-Tyr 3]-
octreotate is a new, promising option for treatment of disseminated gastroenteropancreatic …

Background: The combination of radiopeptide therapy [peptide receptor radionuclide
therapy (PRRT)] with radiosensitizing chemotherapy of gastroenteropancreatic …

Objective Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a
novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For the …

Response Evaluation Criteria In Solid Tumors (RECIST)(unidimensional), Southwest
Oncology Group (SWOG) solid tumor response criteria (bidimensional), and their modified …

Purpose We assessed the outcome and toxicity of salvage therapy (repeat treatment) with
177 Lu-octreotate and high cumulative activities in patients with metastatic …

Quality of life (QOL) is an important outcome in cancer therapy. In this study, we investigated
the QOL and symptoms after [177Lu-DOTA0, Tyr3] octreotate (177Lu-octreotate) therapy in …